Authors
Latest:
Pancreatic Cancer: Genetic Subtype Insights, Therapy ImpactPat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.
Latest:
Dostarlimab's Promise in dMMR Locally Advanced Rectal CancerMark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair-deficient rectal cancer about the potential for long-term disease control with this agent.
Latest:
Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and DrawbacksIn the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Latest:
Managing R/R Multiple Myeloma: Current Strategies and Future Directions in Community PracticeThe panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR T-cell therapy while carefully monitoring for and managing toxicities through established protocols. Key considerations include implementing systematic toxicity management strategies, maintaining long-term patient monitoring, and staying informed about emerging therapeutic options. The field is evolving with promising novel agents and combination approaches being investigated, particularly for patients who progress after initial treatments.
Latest:
The Future of Treating Small Cell Lung CancerKartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.
Latest:
Neoadjuvant Mitomycin C Before TURBT for NMIBC: Safety and Potential Delayed BenefitA phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.
Latest:
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Latest:
Considering Unmet Needs of Premenopausal Patients With Breast CancerYeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.
Latest:
About the Continued Evaluation of MK-1084 for NSCLC and MoreCarlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Latest:
Quality of Life Considered When Starting Treatment in MDSMikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
Latest:
Whether Telehealth or In Person, Palliative Care Offer Benefits for Patients With Advanced Lung CancerJoseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.
Latest:
Evaluating Ways of Measuring MRD in Hematologic MalignanciesJerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Latest:
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare CancersThe study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Latest:
CBM588 With Cabozantinib/Nivolumab Shows Promise in Metastatic RCCHedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.
Latest:
High PSA Before HIFU Tied to Increased Recurrence, Treatment FailureHigh prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.
Latest:
Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene AmplificationsSenthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain MetsNancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.
Latest:
Navigating the Challenges of Advanced Cancer Remission TestingDong Chen, MD, PhD, discusses the obstacles and opportunities for growth in posttreatment cancer detection.
Latest:
Biomarker Analysis Predicts Post-Osimertinib Response in EGFR+ NSCLCBenjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Latest:
Increased Rates of Viral Infections in Multiple MyelomaHeinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Latest:
Spiegel Discusses the Phase 2 Study Evaluating CRG-022 in R/R LBCLJay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.
Latest:
uGDB Predicts Response to Cretostimogene in BCG-Unresponsive NMIBCColin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.
